All conditions

Mesothelioma

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

468
Trials on record
84
Recruiting now
3
Australian sites
1
Phase 3 trials
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Mesothelioma →

Get alerts when Mesothelioma trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Mesothelioma

Mesothelioma is a type of cancer that develops in the thin layer of tissue that lines certain organs in the body, most commonly the lungs and chest cavity. This lining is called the mesothelium. The cancer is almost always linked to past exposure to asbestos, a fibrous material that was widely used in building and construction products throughout Australia for much of the 20th century. Because symptoms can take anywhere from 20 to 50 years to appear after exposure, many people are diagnosed later in life, often in their 60s, 70s, or 80s.

Australia has one of the highest rates of mesothelioma in the world, largely because of the country's heavy use of asbestos in homes, ships, factories, and other workplaces before it was fully banned in 2003. Around 700 to 800 Australians are diagnosed each year. The disease is more common in men, reflecting historical patterns of who worked in industries like construction, mining, and manufacturing, though women and family members can also be affected through indirect contact with asbestos fibres brought home on clothing.

Treatment is managed by a team of specialists and is planned based on the type and stage of the cancer, as well as a person's overall health. Options that doctors commonly discuss include chemotherapy, immunotherapy, radiation therapy, and in some cases surgery. The focus of treatment may be on slowing the cancer's growth, managing symptoms, or both. Palliative care, which helps people feel as comfortable as possible, is also an important part of care at any stage. Your medical team is the best source of information about what options may be relevant for your specific situation.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Mesothelioma in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

Research pipeline

Where trials for Mesothelioma currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Mesothelioma.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Mesothelioma by country. Australia is highlighted.

Showing the top 10 of 41 countries with trial sites.

Clinical trials for Mesothelioma

Showing 94 of 94 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT02460224 · Novartis Pharmaceuticals Phase 2 · 12 countries Completed
Completed Phase 2 Est. completion 31 December 2020
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE Hong Kong🇮🇹 IT🇯🇵 JP +4 more

**Who might be able to join this trial:** - (Phase I part) You have an advanced or spreading solid tumour cancer that can or cannot be measured on scans, and your cancer has continued to grow despite standard treatment, you could not tolerate standard treatment, or no standard treatment exists for your cancer. - (Phas...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02610140 · Bayer Phase 2 · 14 countries Completed
Completed Phase 2 Est. completion 31 May 2017
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇫🇮 FI🇫🇷 FR🇮🇹 IT🇳🇱 NL🇵🇱 PL +6 more

**Who might be able to join this trial:** - You have been diagnosed with malignant pleural mesothelioma (a type of cancer affecting the lining of the lungs) that has been confirmed by a tissue sample, and your cancer produces high levels of a protein called mesothelin. - Your cancer cannot be removed by surgery and has...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02709512 · Polaris Group Phase 3 · 5 countries Completed
Completed Phase 3 Est. completion 15 August 2022
🇦🇺 AU🇮🇹 IT🇹🇼 TW🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been confirmed by a tissue biopsy to have a type of mesothelioma (a cancer affecting the lining of the lungs) that cannot be removed by surgery, and it is either the "biphasic" or "sarcomatoid" type - You have not yet received any chemotherapy or immunotherapy treatm...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02899299 · Bristol-Myers Squibb Phase 3 · 21 countries Completed
Completed Phase 3 Est. completion 25 March 2020
🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇱 CL🇨🇳 CN🇨🇴 CO🇫🇷 FR🇩🇪 DE +13 more

Who might be able to join this trial: - You must be at least 18 years old (male or female) - You must have been diagnosed with pleural malignant mesothelioma (a type of cancer affecting the lining of the lungs) that cannot be treated with surgery to cure it - You must be well enough to carry out everyday activities wit...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03710876 · Ferring Ventures Limited Phase 3 · 9 countries Completed
Completed Phase 3 Est. completion 29 March 2024
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇹 IT🇵🇱 PL🇷🇺 RU🇬🇧 GB +1 more

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of giving consent - People who are able to give their own informed consent to participate - People who have a confirmed tissue-sample diagnosis of a specific type of cancer called malignant pleural mesothelioma (MPM), where...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04665206 · Vivace Therapeutics, Inc Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 2 November 2029
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with mesothelioma (a type of cancer affecting the lining of organs) that has spread or cannot be removed by surgery, and you have not yet received any systemic (whole-body) treatment — this applies to both chest (pleural) and non-chest forms (Cohort A...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05086692 · Medicenna Therapeutics, Inc. Phase 2 · 7 countries Recruiting
Recruiting Phase 2 Est. completion 30 June 2026
🇦🇺 AU🇨🇦 CA🇮🇪 IE🇵🇹 PT🇰🇷 KR🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You are fairly active and able to care for yourself, with little or no limitation on daily activities (this is measured by a standard scale called ECOG, scored 0 or 1) - You are willing and able to sign a consent form and follow all study r...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06535607 · AstraZeneca Phase 2 · 12 countries Recruiting
Recruiting Phase 2 Est. completion 30 November 2028
🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇳 CN🇩🇪 DE🇮🇹 IT🇯🇵 JP🇰🇷 KR +4 more

**Who might be able to join this trial:** - You must be 18 years of age or older at the time of signing the consent form. - You may need to provide a tumor tissue sample to check for a specific protein called PD-L1 (if this applies to your situation). - You must be fairly active and able to care for yourself — able to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01907100 · Boehringer Ingelheim Phase 3 · 27 countries Terminated
Terminated Phase 3 Est. completion 16 March 2018
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇱 CL🇭🇷 HR🇨🇿 CZ +19 more

Who might be able to join this trial: - You have been diagnosed with a type of cancer called malignant pleural mesothelioma (MPM), confirmed by a tissue sample, and your specific subtype is either "epithelioid" or "biphasic" (or only "epithelioid" depending on which part of the trial you would join) - Your doctor belie...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02357147 · Morphotek Phase 2 · 6 countries Terminated
Terminated Phase 2 Est. completion 30 November 2018
🇦🇺 AU🇫🇷 FR🇩🇪 DE🇮🇹 IT🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You must be at least 18 years old at the time you give your consent to join - You must have a confirmed diagnosis of malignant pleural mesothelioma (MPM) that cannot be removed by surgery, and it must be the "epithelial" type (a specific cell type of this cancer) - A stored...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04914897 · Sanofi Phase 2 · 11 countries Terminated
Terminated Phase 2 Est. completion 18 July 2023
🇦🇷 AR🇦🇺 AU🇨🇱 CL🇫🇷 FR🇮🇹 IT🇯🇵 JP🇵🇱 PL🇰🇷 KR +3 more

**Who might be able to join this trial:** - You must be 18 years of age or older (or the legal adult age in your country) at the time of signing the consent form - You have been diagnosed with Stage IV non-small cell lung cancer (advanced lung cancer that has spread), confirmed by a tissue or cell sample — this applie...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07550049 · University of Kansas Medical Center Not Applicable Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 April 2029

**Who might be able to join this trial:** - You are able to understand the study and are willing to sign a consent form to participate (note: signing this form remotely may be allowed). - You are willing to follow all study procedures and are available for the full length of the study. - You are 18 years of age or olde...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00242723 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

Who might be able to join this trial: - You have a suspicious spot on your lung or esophagus, or have been diagnosed with a cancer in the chest area (such as lung cancer, esophageal cancer, mesothelioma, thymoma, or a cancer that has spread to the chest from another part of the body). - You are generally well enough to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01617382 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇧🇪 BE

Who might be able to join this trial: - You have cancer that has spread to the lining of your abdomen (belly), coming from colorectal (bowel) cancer, a condition called pseudomyxoma peritonei, or a type of cancer called peritoneal mesothelioma - You are already scheduled to have a major surgery to remove as much cancer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01950572 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 July 2033
🇺🇸 US

**Who might be able to join this trial:** - You are 2 years of age or older and have been diagnosed with malignant mesothelioma (a type of cancer affecting the lining of certain organs) - You are 18 years of age or older and have been diagnosed with thymic carcinoma, pancreatic or bile duct cancer, lung cancer, stomach...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02012699 · University of Nebraska Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2099
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with cancer or have a history of cancer - You are considered at risk of developing cancer, or you have some unusual findings that need further investigation - You have no history of cancer and would be joining as a normal comparison participant - You are a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02073500 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2022
🇳🇴 NO

Who might be able to join this trial: - You must be over 18 years old - You must have a confirmed diagnosis of cancer that has spread to the lining of the abdomen (called peritoneal surface malignancy) - You must be considered suitable for a specific type of surgery that combines tumour removal with heated chemotherapy...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03007030 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - You are willing to give written agreement to take part, and you understand you can leave the study at any time without it affecting your regular medical care - If you are a woman, you are either past menopause for at least one year, have had a surgical procedure that means y...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03556228 · VM Oncology, LLC Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with certain types of cancer confirmed by a lab test, including head and neck cancers, esophageal cancer, lung cancers, mesothelioma, pancreatic cancers, or any solid tumour or lymphoma that has a specific gene change called NTRK1 fusion — and...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03683680 · Dana-Farber Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇺🇸 US

Who might be able to join this trial: - Adults who have been diagnosed with malignant pleural mesothelioma (a type of cancer affecting the lining of the lungs) - People who are scheduled to undergo a diagnostic pleural biopsy (a procedure to take a small tissue sample from around the lungs for testing) - People who are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03760575 · Abramson Cancer Center at Penn Medicine Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 February 2027
🇺🇸 US

**Who might be able to join this trial:** - You must be willing and able to sign a written consent form agreeing to take part in the trial. - You must be at least 18 years old on the day you sign the consent form. - Your cancer must be measurable using standard imaging guidelines (confirm with trial site). - You must...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03830229 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2032
🇺🇸 US

**Who might be able to join this trial:** **Group 1 (people with mesothelioma):** - You have been diagnosed with mesothelioma, confirmed by a pathology test - You have a harmful inherited change (mutation) in a gene called BAP1, identified through either a research or clinical test - You are at least 2 years old **Gr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03917043 · Ascentage Pharma Group Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with non-small cell lung cancer (NSCLC) with a specific gene change (ALK or ROS1 fusion), malignant pleural mesothelioma, esophageal cancer, or ovarian cancer at an advanced stage (for the initial phase of the trial). - For the expansion phase: either...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04115254 · Dana-Farber Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a cancer that your doctor has recommended treating with a precise, targeted form of radiation called stereotactic body radiation therapy (SBRT). - Your tumor is no larger than 7 centimeters (about the size of a small apple). - You are 18 years of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04400539 · University Hospital, Lille Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 9 May 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are generally able to carry out daily activities without much difficulty (good physical functioning, confirmed with trial site) - You have been diagnosed with a type of cancer affecting the lining of the lung (malignant pleural mesothelioma) that cannot be removed by sur...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04431024 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2038
🇺🇸 US

**Who might be able to join this trial:** - You have a personal history of any cancer and it is known or suspected that you carry a specific inherited gene change involving a gene called BAP1 - **Or**, you are a close blood relative (parent, child, sibling, grandparent, aunt/uncle, or first cousin) of someone who has...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04515836 · University of Chicago Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 April 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been formally diagnosed with malignant mesothelioma by a doctor. - People who are willing to sign a consent form of their own free will and agree to follow the study's requirements before any study procedures begin. - People who are willing to undergo genetic...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04792463 · Mohamed Abdel-Rahman Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** - You have personally had one cancer linked to a condition called BAP1 cancer predisposition syndrome, AND at least two close relatives (parents, siblings, children, grandparents, aunts/uncles, or cousins) have also had cancers associated with this condition (such as eye melan...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04847063 · National Cancer Institute (NCI) Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 December 2033
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with cancer that has spread to the lining of the abdomen (called peritoneal carcinomatosis), coming from mesothelioma, an unusual cell growth in the abdomen lining, or from appendix, colon/rectal, or ovarian cancer — confirmed by the NCI's pathology l...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04981119 · A2 Biotherapeutics Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** **Part 1:** - You have been diagnosed with a confirmed solid tumor — such as colorectal cancer, non-small cell lung cancer, or pancreatic cancer — that has spread to other parts of the body, cannot be surgically removed, or where your doctor believes there is a high risk it co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04996017 · Gruppo Oncologico Italiano di Ricerca Clinica Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 July 2027
🇮🇹 IT

**Who might be able to join this trial:** - People who have signed a consent form agreeing to take part in the study - People aged 18 or older at the time of signing the consent form - People who have been diagnosed with malignant pleural mesothelioma (a type of cancer affecting the lining of the lungs), confirmed thr...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05001880 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 August 2026
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older. - People with a confirmed diagnosis of malignant peritoneal mesothelioma (a cancer affecting the lining of the abdomen) who have not yet received any treatment for it. Note: certain slow-growing subtypes (well-differentiated papillary mesothelioma and mul...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05107674 · Nurix Therapeutics, Inc. Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 31 August 2026
🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older. - People whose cancer can be measured on scans or tests according to standard criteria for their cancer type. - People whose cancer has spread to other parts of the body or cannot be removed by surgery, and who have already received standard treatmen...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05188859 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been diagnosed with malignant pleural mesothelioma (a type of cancer affecting the lining of the lungs) that cannot be surgically removed, is locally advanced (stage IIIB), has come back after previous treatment, or h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05245500 · Bristol-Myers Squibb Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 10 December 2027
🇺🇸 US

**Who might be able to join this trial:** - Your cancer has been confirmed by a lab test (biopsy) to be a solid tumor that has a specific gene change called a homozygous deletion of the MTAP gene in the tumor tissue. - Your cancer cannot be removed by surgery, or it has spread to other parts of the body. - You have a t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05304208 · Erasmus Medical Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2025
🇳🇱 NL

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of mesothelioma (a cancer affecting the lining of the lung) called epithelioid MPM, confirmed by laboratory testing of tissue samples, and who are eligible to receive 2 to 4 cycles of platinum-based chemotherapy. - People w...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05538806 · NovoCure Ltd. Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇩🇪 DE🇮🇹 IT🇳🇱 NL

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with pleural mesothelioma (a type of cancer affecting the lining of the lungs) that has been confirmed by a tissue sample, and surgery to remove the cancer completely is not an option - Your doctor plans to treat you with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05579366 · Genmab Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇨🇳 CN🇯🇵 JP🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with certain types of advanced or spreading cancer that cannot be surgically removed, confirmed by lab testing — including ovarian, endometrial, lung, breast, cervical, or mesothelioma cancers (the specific type accepted depends on which part of the t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05627960 · A&G Pharmaceutical Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older. - You must have been diagnosed with advanced cancer, confirmed by a tissue or cell sample test. - Your cancer must show at least one measurable tumor that can be seen on a scan. - You must have tried one or more standard cancer treatment...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05628376 · University College, London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 October 2030
🇬🇧 GB

**Who might be able to join this trial:** **All groups:** - You must be willing and able to give written consent to take part - You must agree to attend follow-up appointments every 3 months for the first 2 years, then every 6 months after that - You must be able to attend follow-up at a participating TRACERx EVO clin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05647265 · Alliance for Clinical Trials in Oncology Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of pleural mesothelioma (a cancer of the lining of the lungs) that is classified as "sarcomatoid" or mostly sarcomatoid (more than 50% biphasic type). - Your cancer is at an early to moderate stage (Stage I to IIIA) based on stand...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05655078 · University College, London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2029
🇬🇧 GB

**Who might be able to join this trial:** - You are 18 years of age or older and have been diagnosed with malignant pleural mesothelioma (a type of cancer affecting the lining of the lungs), confirmed by a tissue biopsy that also identified the specific type - Your cancer has not spread to distant parts of the body, an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05703854 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with advanced clear cell renal cell carcinoma (a type of kidney cancer), osteosarcoma (a type of bone cancer), or mesothelioma (a cancer linked to the lining of the lungs or other organs), where a tumour sample shows a specific protein called CD70 at certain...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05730816 · Brigham and Women's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 3 April 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older and have been diagnosed with malignant mesothelioma (a type of cancer) - You are scheduled to have surgery with a specific procedure called HIOC performed by Dr. Raphael Bueno or another thoracic (chest) surgeon at BWH (Brigham and Women's Hospit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05765084 · University Hospital, Antwerp Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇧🇪 BE

**Who might be able to join this trial:** - People who have given signed consent to take part in the study - People who have been diagnosed with a specific type of chest lining cancer called epithelioid malignant pleural mesothelioma (MPM) that cannot be removed by surgery, confirmed by a tissue sample (any stage) - P...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05873686 · Nuvectis Pharma, Inc. Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 March 2027
🇬🇧 GB🇺🇸 US

**Part A (Early phase – open to various solid tumours)** Who might be able to join this trial: - People aged 18 or older who are willing and able to provide written consent to participate - People with advanced, spreading, or worsening solid tumour cancers where no effective standard treatment is available, or where s...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05930665 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with malignant mesothelioma in the lining of the lungs (confirmed by a tissue test), and surgery to cure it is not an option for you. - You are generally well enough to carry out light activity and care for yourself (based on a standard fitness scale s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05932199 · Baylor College of Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 May 2028
🇺🇸 US

**Who might be able to join this trial:** - You have a type of cancer called malignant pleural mesothelioma (MPM) that a specialist surgeon believes may be removable with surgery, based on scans showing the cancer has not spread beyond one side of the chest - You are willing to undergo planned surgery to remove the tu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05944237 · Cancer Research UK Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇬🇧 GB

**Who might be able to join this trial:** - People who have given written consent and are able to cooperate with the study treatment and follow-up visits - People aged 18 or older at the time of giving consent - People with an advanced solid tumour cancer that has been confirmed by laboratory testing of tissue or cell...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06031636 · Tianjin Medical University Second Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (including those ages exactly) - You have been diagnosed with late-stage mesothelioma (a type of cancer affecting the lining of the lungs or chest) and previous immunotherapy treatment has not worked - You (or your legal representative) are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06037941 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇺🇸 US

Who might be able to join this trial: - You are between 30 and 85 years old - You have no previous history of chest (thoracic) cancer or cancers from other parts of the body (such as breast, stomach, colon, or pancreas) that could have spread to the lining of the lungs - You have recently been diagnosed with MPM (malig...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06051695 · A2 Biotherapeutics Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2028
🇺🇸 US

**Who might be able to join this trial:** - You must already be enrolled in a related study called BASECAMP-1, with tumor tissue showing a specific genetic marker (called "loss of HLA-A\*02"), and have had a successful blood collection process with enough cells stored for treatment - You have been diagnosed with one o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06057935 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 21 September 2028
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older (any sex) - You have been diagnosed with a type of cancer called malignant peritoneal mesothelioma (MPM) at the enrolling hospital - During surgery, a tissue sample has confirmed your mesothelioma is the "epithelioid" type (a specific subtype...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06196294 · Second Affiliated Hospital of Guangzhou Medical University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 November 2030
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with advanced cancer that produces a specific protein called GPC3 or Mesothelin. - Doctors expect you to live for more than 12 weeks. - Your heart, lungs, liver, kidneys, and blood are working well enough to meet the trial's health requirements. - A sp...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06251310 · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Da... Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 18 January 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a solid cancer that has spread or cannot be surgically removed, and your cancer has not responded to or has gotten worse after standard treatments (such as chemotherapy, immunotherapy, radiation, or targeted therapy), or no standard treatment is...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06362369 · 7 Hills Pharma, LLC Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older. - People who have been diagnosed (confirmed by tissue testing) with certain advanced or spreading cancers, including: melanoma, pleural mesothelioma, kidney cancer (renal cell carcinoma), a specific type of bowel cancer (MSI-high or mismatch repair-d...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06444815 · KaliVir Immunotherapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 September 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with an advanced, inoperable, or spreading solid tumour that has been confirmed by a lab test (pathology). - Your cancer is one of several types of interest, including breast, bladder, cervical, colorectal, oesophageal, head and neck, kidney, ovarian,...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06452160 · BridGene Biosciences Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You have signed a consent form agreeing to take part in the study - You are male or female and are 18 years old or older - Your doctor expects you to live for at least 12 weeks - You are generally able to carry out daily activities with little or no difficulty (this is measu...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06477419 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 21 June 2029
🇺🇸 US

Who might be able to join this trial: - You (or your legal representative) are willing and able to sign a written consent form - You are 18 years old or older at the time of signing consent - You have been diagnosed with diffuse pleural mesothelioma (a type of cancer affecting the lining of the lungs), confirmed throug...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06491784 · NHS Greater Glasgow and Clyde Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2025
🇬🇧 GB

Who might be able to join this trial: - You have been diagnosed with mesothelioma, and this diagnosis has been confirmed by a specialist team of doctors who focus on this condition. - You are reasonably active and able to carry out daily activities with little or no difficulty (this is measured using a standard scale c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06503146 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2028
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with one of the following cancers (confirmed by a tissue sample/biopsy): pancreatic cancer, bile duct cancer (cholangiocarcinoma), liver cancer (hepatocellular carcinoma), stomach cancer, bladder cancer, ovarian cancer, a tumor of the adrenal gland or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06536179 · Marco Emilio Bianchi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 July 2025
🇮🇹 IT

**Who might be able to join this trial:** **For people with mesothelioma:** - You have been suspected of having, or have already been diagnosed with, pleural mesothelioma (a cancer affecting the lining of the lungs) - You are being considered for surgery - You are 18 years of age or older (men and women, including wom...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06538376 · Brigham and Women's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇺🇸 US

**Who might be able to join this trial:** - You must be an adult aged 18 or older (whether or not you are on a breathing machine) - You likely have a condition affecting how your diaphragm moves, how your lungs are working, fluid in your lungs, or difficulty swallowing safely - You, or someone legally authorised to mak...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06543069 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2026
🇨🇳 CN

**Who might be able to join this trial:** - You fully understand the study and are willing to sign a consent form agreeing to take part - You are 18 years of age or older - You have been confirmed by a lab test (tissue or cell sample) to have peritoneal mesothelioma (a cancer affecting the lining of the abdomen) - You...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06566079 · InSilico Medicine Hong Kong Limited Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 31 August 2027
🇨🇳 CN🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with advanced or spreading malignant mesothelioma or another solid tumour that cannot be surgically removed, and standard treatments have not worked or no standard treatment is available - If you have mesothelioma, you...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06581549 · Istituto Oncologico Veneto IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with mesothelioma affecting the lining of the lungs (pleura) or the lining of the abdomen (peritoneum) - You are over 18 years of age - If you are having surgery, both a small tissue sample (biopsy) and a larger surgical tissue sample must be available - A...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06637345 · Centro di Riferimento Oncologico - Aviano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 March 2027
🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years of age or older - You are able to understand, agree to, and sign a consent form - You have been diagnosed with malignant pleural mesothelioma (a type of cancer affecting the lining of the lungs) confirmed by a tissue sample test - You have previously received...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06638931 · Instituto do Cancer do Estado de São Paulo Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇧🇷 BR

**Who might be able to join this trial:** - You are 18 years of age or older. - Your tumor tissue test (a lab test called immunohistochemistry) shows a PD-L1 "combined positive score" (CPS) of 10 or higher (confirm with trial site). - Your cancer has gotten worse or you could not tolerate the standard treatments that...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06710756 · Perspective Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2028
🇺🇸 US

Who might be able to join this trial: - You must be 18 years old or older - Your liver, kidneys, and other organs must be working well enough, as shown by blood tests - You must be relatively active and able to care for yourself, with only mild limitations on daily activities (this is measured using a standard scale ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06726564 · Suzhou Maximum Bio-tech Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to participate and have signed a consent form agreeing to take part - You are 18 years old or older, any gender - You have been diagnosed with an advanced solid tumour cancer that has caused a build-up of fluid around the lungs (malignant pleural effusion) co...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06756035 · Context Therapeutics Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are generally healthy and able to carry out daily activities with little to no limitation (this is measured by a standard scale called ECOG, scored 0 or 1) - Your cancer can be measured or evaluated using standard imaging guidelines - Your organs (such as liver, kidneys,...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06790082 · Aalborg University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2027
🇩🇰 DK

Who might be able to join this trial: - You have spots or growths in the lining of your lungs (pleura) that doctors suspect could be mesothelioma, and you have been referred for a biopsy of that area. - You have had or are currently having a type of scan called an FDG PET/CT scan as part of investigating the suspicious...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06840834 · Intergroupe Francophone de Cancerologie Thoracique Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 24 March 2026
🇫🇷 FR

**Who might be able to join this trial:** - People who have given written consent to take part before any trial-related procedures begin, and who are willing and able to attend scheduled visits and follow testing requirements. - People who have been diagnosed with Pleural Mesothelioma confirmed through a tissue biopsy...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06875076 · The First Hospital of Jilin University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇨🇳 CN

**Who might be able to join this trial:** - People of Asian ethnicity, aged between 18 and 75, who are generally able to carry out normal daily activities with little or no restriction (confirm with trial site regarding the activity level assessment) - People who have been diagnosed with malignant pleural mesothelioma...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06885697 · National Cancer Institute (NCI) Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2034
🇺🇸 US

**Who might be able to join this trial:** - People who have mesothelioma (a specific type of cancer) that cannot be surgically removed, has spread, or has come back, or who have other solid tumour cancers that produce a protein called mesothelin. For mesothelioma, only certain tumour types (epithelioid or mostly epith...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06886672 · Fondazione IRCCS Policlinico San Matteo di Pavia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2025
🇮🇹 IT

**Who might be able to join this trial:** **Group A (for people with a diagnosed illness):** - You have been formally diagnosed with malignant pleural mesothelioma (a type of cancer affecting the lining of the lungs, often linked to asbestos exposure), at any stage and regardless of what treatments you may have alread...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06907095 · Gustave Roussy, Cancer Campus, Grand Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2030
🇫🇷 FR

**Who might be able to join this trial:** **General requirements (all participants in the higher-risk group must meet these):** - Adults aged 18 or older - Able to understand and read spoken and written French - Willing to follow the study requirements and attend follow-up - Able to use the internet via a phone or com...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06910449 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇪🇬 EG

Who might be able to join this trial: - You have cancer that has spread to other parts of the body (metastatic disease). - You have had a surgical procedure to remove the lining around the lungs (pleural decortication). - You are able to understand and agree to take part by signing a consent form. Who may not be able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06946498 · National and Kapodistrian University of Athens Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇬🇷 GR

**Who might be able to join this trial:** - You have fluid build-up around your lungs that has not yet been diagnosed, and tests show it is a specific type of fluid rich in certain white blood cells (called a lymphocytic exudate) (confirm with trial site) **Who may not be able to join:** - You have an infection causin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06971848 · University Hospital, Angers Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are currently being treated with one of the specific medications being studied (Atezolizumab, Nivolumab, Obinutuzumab, Durvalumab, Pembrolizumab, Daratumumab, or Cemiplimab) and have received at least two doses of it without any suspected allergic reactions. - You have he...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06996249 · Dutch Society of Physicians for Pulmonology and Tuberculosis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇳🇱 NL

Who might be able to join this trial: - You must be 18 years old or older - You have been diagnosed with a chest (thoracic) cancer confirmed by a tissue or cell sample, or your medical team strongly suspects you may have one based on scans and specialist discussions - You are willing to give your permission for your he...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07121374 · University Hospital, Antwerp Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2028
🇧🇪 BE

**Who might be able to join this trial:** - You are able to give written consent and are willing to follow the study procedures - You have been diagnosed with a specific type of mesothelioma (epithelioid pleural mesothelioma) confirmed by a tissue test, at a stage that is currently considered inoperable (not suitable...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07126509 · University of Chicago Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇺🇸 US

Who might be able to join this trial: - You must have a confirmed diagnosis of a specific type of mesothelioma (called "epithelioid" subtype) affecting the lining of the lung, confirmed through a surgical biopsy procedure. - The cancer must be located only on one side of the chest. - Your cancer must be considered eith...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07192900 · David Bartlett, MD Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2032
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed (confirmed by biopsy) with cancer that has spread to the lining of the lung (pleura), or mesothelioma, and you have fluid buildup around your lungs — and your cancer has not responded to standard treatments available for your cancer type. - You are at...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07277413 · IDEAYA Biosciences Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 April 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older (or the minimum age required by local rules) at the time of signing the consent form - People who have a laboratory-confirmed diagnosis of a locally advanced, returning, or spread solid tumour of a specific type that has a genetic chan...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07330271 · Beijing Tsinghua Chang Gung Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2029
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with a specific type of cancer called epithelioid or biphasic malignant peritoneal mesothelioma, confirmed by a tissue test - You are already planned to have a major surgery to remove tumours from the abdomen, along w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07403630 · Azienda Ospedaliero-Universitaria di Parma Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇮🇹 IT

**Who might be able to join this trial:** - You are 1 year old or older and are being seen at one of the participating hospitals (located in Parma, Perugia, or Palermo, Italy). - You have been diagnosed with a blood cancer or a solid tumour (a growth or lump), including cancers that are more common in children. - Your...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07443020 · Allegheny Singer Research Institute (also known as Allegheny Health Ne... Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2033
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with cancer that has spread to the lining of the lungs (pleura), or mesothelioma, confirmed by a biopsy, and you are experiencing fluid build-up around the lungs. - You have already tried standard treatments for your cancer type and those treatments a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07510815 · Beijing Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 14 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old at the time of signing consent. - You have been diagnosed with malignant pleural mesothelioma (in the lining of the lungs) or malignant peritoneal mesothelioma (in the lining of the abdomen), confirmed by a tissue sample, and the disease ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07532902 · Memorial Sloan Kettering Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 April 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with one of three specific cancers, confirmed by a pathologist: diffuse pleural mesothelioma (a cancer of the lining around the lungs), gastroesophageal carcinoma (cancer of the esophagus, the junction between the esophagus and stomach, or the...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07561190 · Azienda USL Reggio Emilia - IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2024
🇮🇹 IT

Who might be able to join this trial: - You are willing and able to give your informed consent to take part in the study - You are over 18 years old - You have been diagnosed with MPM (a type of cancer called malignant pleural mesothelioma) that has been confirmed through a tissue sample test - Biological samples (such...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07563738 · Orion Corporation, Orion Pharma Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2029
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People whose general health and ability to carry out daily activities is rated at 0 or 1 on a standard oncology fitness scale (meaning fully active or restricted in strenuous activity only) - People whose treating doctor estimates the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07705334 · SHY Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 May 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People whose doctors estimate they have more than 3 months to live - People who are largely able to carry out daily activities with little or no restriction (confirm with trial site what this means for a specific situation) - People w...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00003508 · Burzynski Research Institute Phase 2 · 1 country Terminated
Terminated Phase 2 Est. completion 26 April 2005
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with stage IV mesothelioma (confirmed by a tissue sample/biopsy) that is unlikely to respond to current treatments and cannot be cured with existing therapies - Your cancer has been detected by a CT scan or MRI - You are aged 1 or older - You are reasonabl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Mesothelioma. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

There is no single national mesothelioma organisation. Support is available through state based asbestos disease organisations, such as the Asbestos Council of Victoria/GARDS and the Asbestos Diseases Society of South Australia, and through the National Centre for Asbestos Related Diseases in WA.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.